Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rule

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|May 24, 2020
The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphomaDavid Tucker, Nick Morley, Peter MacLean, et al.
British Journal of Haematology|April 18, 2024
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinibJeff P Sharman, Paolo Ghia, Paulo Miranda, et al.
Leukemia & Lymphoma|July 13, 2014
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Virginia Amador, Mary Callanan, et al.
Antiviral Therapy|August 4, 2020
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring systemMichael A Jarvis, Frederick A Hansen, Kyle Rosenke, et al.
British Journal of Haematology|March 10, 2020
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survivalMark J Bishton, Simon Rule, William Wilson, et al.
Advances in Therapy|October 7, 2017
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical DevelopmentAndrew Davies, Claude Berge, Axel Boehnke, et al.
Haematologica|December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaAndrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
Leukemia & Lymphoma|April 26, 2021
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignanciesWojciech Jurczak, Simon Rule, William Townsend, et al.
Clinical Pharmacokinetics|November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphomaAndrzej Hellmann, Simon Rule, Jan Walewski, et al.
British Journal of Haematology|February 4, 2020
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapyRory McCulloch, Carlo Visco, Toby A Eyre, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|May 24, 2020
The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphomaDavid Tucker, Nick Morley, Peter MacLean, et al.
British Journal of Haematology|April 18, 2024
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinibJeff P Sharman, Paolo Ghia, Paulo Miranda, et al.
Leukemia & Lymphoma|July 13, 2014
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Virginia Amador, Mary Callanan, et al.
Antiviral Therapy|August 4, 2020
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring systemMichael A Jarvis, Frederick A Hansen, Kyle Rosenke, et al.
British Journal of Haematology|March 10, 2020
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survivalMark J Bishton, Simon Rule, William Wilson, et al.
Advances in Therapy|October 7, 2017
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical DevelopmentAndrew Davies, Claude Berge, Axel Boehnke, et al.
Haematologica|December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaAndrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
Leukemia & Lymphoma|April 26, 2021
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignanciesWojciech Jurczak, Simon Rule, William Townsend, et al.
Clinical Pharmacokinetics|November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphomaAndrzej Hellmann, Simon Rule, Jan Walewski, et al.
British Journal of Haematology|February 4, 2020
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapyRory McCulloch, Carlo Visco, Toby A Eyre, et al.
Pageof 8